Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Time-Restricted eating shows promise for psoriasis inflammation

NCT ID NCT04728165

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 5 times

Summary

This pilot study tested whether time-restricted feeding (eating all daily calories between 8am and 2pm, then fasting for 18 hours) could reduce inflammation in men with mild to moderate psoriasis. 27 participants (including healthy volunteers) stayed at the clinic for 4.5 days, wore glucose monitors, and completed meal tests. The study measured changes in immune cell activity and other markers of inflammation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
time-restricted feeding (eating only between 8am and 2pm each day)
What this could lead to
If it works, this could point toward a simple dietary approach to help manage inflammation in psoriasis.
What could go wrong
This is a very small pilot study (27 people) that only looks at blood markers, not actual skin improvement. It may not lead to any practical treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

27 people

The number who actually took part.

Started

Jun 2021

Finished

Jul 2023

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Males between the ages of 18 and 70 with mild to moderate active psoriasis by PASI score for inclusion in psoriasis group Age (plus or minus 5 yrs) and BMI (plus or minus 5 kg/m2) matched control male subjects for inclusion in the control group. Ability to provide informed consent Willingness and ability to participate in study procedures

Ages

18 to 80 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: Individuals must meet the inclusion criteria listed below in order to be eligible to participate in the study. * Males between the ages of 18 and 80 with mild to moderate active psoriasis by PASI score for inclusion in psoriasis group * Age (plus or minus 10 yrs) and BMI (plus or minus 5 kg/m\^2) matched control male subjects for inclusion in the control group. * Ability to provide informed consent * Willingness and ability to participate in study procedures EXCLUSION CRITERIA: * Severe psoriasis by PASI (Psoriasis Area and Severity Index) score \> 12 * Treatment with systemic biologic immune modifying agents within the last 2 months. * Currently on treatment for allergies or other inflammatory diseases. * Has taken Vitamin B or tryptophan supplementation within 2 weeks of participation. * Unwillingness/inability to provide informed consent. * Individuals with known history of type 1 and 2 diabetes mellitus or other metabolic conditions that would interfere with study parameters including chronic kidney disease, chronic liver disease, history of hypoglycemia * On treatment with medication that would interfere with study parameters including anti-hyperglycemic medications, systemic steroids, adrenergic-stimulating agents, other medications known to affect sleep, circadian rhythms or metabolism. * Caffeine in excess of three 8 oz cups per day. * Factors that affect circadian rhythm including individuals who perform overnight shift work, irregular sleep and/ or eating schedules, regularly fast for more than 15 hours/ day * Regular use of tobacco product within last 3 months. * Consuming more than 3 servings of alcohol/ day * Engaged in competitive sports training * Moderate to severe claustrophobia * Unstable weight with more than 5% body weight change in last 3 months * Food allergies or intolerances or dietary patterns that would prohibit consumption of the metabolic diet or mixed meal test.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.